Richard Law
Stock Analyst at Goldman Sachs
(3.99)
# 591
Out of 5,124 analysts
70
Total ratings
35.29%
Success rate
22.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Buy | $26 → $38 | $25.00 | +52.00% | 7 | Dec 11, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $120 → $135 | $100.59 | +34.21% | 1 | Nov 18, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Neutral | $19 → $29 | $29.04 | -0.14% | 2 | Oct 30, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Neutral | $35 → $40 | $46.55 | -14.07% | 1 | Sep 26, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $32 → $52 | $36.29 | +43.29% | 7 | Sep 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $27 → $30 | $31.12 | -3.60% | 4 | Aug 7, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $74 → $82 | $13.18 | +522.15% | 4 | Aug 6, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $6.08 | -50.66% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $3.51 | +270.37% | 3 | May 9, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $36 → $31 | $27.16 | +14.14% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $30 | $35.18 | -14.72% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $15.68 | -29.85% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $27.72 | +69.55% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $52.44 | +20.14% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $77.81 | -52.45% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $8.99 | +745.38% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.05 | +582.93% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $11.86 | +414.33% | 4 | May 8, 2023 |
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $26 → $38
Current: $25.00
Upside: +52.00%
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $120 → $135
Current: $100.59
Upside: +34.21%
Arcutis Biotherapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $19 → $29
Current: $29.04
Upside: -0.14%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $46.55
Upside: -14.07%
Mineralys Therapeutics
Sep 9, 2025
Maintains: Buy
Price Target: $32 → $52
Current: $36.29
Upside: +43.29%
Viridian Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $31.12
Upside: -3.60%
MoonLake Immunotherapeutics
Aug 6, 2025
Maintains: Buy
Price Target: $74 → $82
Current: $13.18
Upside: +522.15%
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $6.08
Upside: -50.66%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $3.51
Upside: +270.37%
Celldex Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $27.16
Upside: +14.14%
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $35.18
Upside: -14.72%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $15.68
Upside: -29.85%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $27.72
Upside: +69.55%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $52.44
Upside: +20.14%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $77.81
Upside: -52.45%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $8.99
Upside: +745.38%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.05
Upside: +582.93%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $11.86
Upside: +414.33%